Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
HKD 57.35
(4.08%)
HKD 57.35
(4.08%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.57 Billion CNY | -31.09% |
| 2022 | 3.73 Billion CNY | 212.89% |
| 2021 | 1.19 Billion CNY | 45.96% |
| 2020 | 816.89 Million CNY | 30.98% |
| 2019 | 623.66 Million CNY | 35.17% |
| 2018 | 461.38 Million CNY | 9.96% |
| 2017 | 419.58 Million CNY | 33.24% |
| 2016 | 314.92 Million CNY | 57.1% |
| 2015 | 200.45 Million CNY | 65.34% |
| 2014 | 121.24 Million CNY | 39.43% |
| 2013 | 86.95 Million CNY | 25.72% |
| 2012 | 69.16 Million CNY | -10.38% |
| 2011 | 77.17 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 294.68 Million CNY | 262.89% |
| 2024 Q2 | 238.24 Million CNY | -19.15% |
| 2024 Q3 | 228.53 Million CNY | -4.08% |
| 2023 Q2 | 1.21 Billion CNY | 71.82% |
| 2023 FY | 2.57 Billion CNY | -31.09% |
| 2023 Q4 | 81.2 Million CNY | -85.49% |
| 2023 Q3 | 559.78 Million CNY | -54.11% |
| 2023 Q1 | 709.94 Million CNY | 17.39% |
| 2022 Q3 | 1.13 Billion CNY | -20.29% |
| 2022 FY | 3.73 Billion CNY | 212.89% |
| 2022 Q4 | 604.79 Million CNY | -46.65% |
| 2022 Q2 | 1.42 Billion CNY | 149.48% |
| 2022 Q1 | 570.09 Million CNY | 35.8% |
| 2021 Q1 | 165.15 Million CNY | -30.95% |
| 2021 Q4 | 419.79 Million CNY | 44.34% |
| 2021 FY | 1.19 Billion CNY | 45.96% |
| 2021 Q3 | 290.83 Million CNY | -8.13% |
| 2021 Q2 | 316.57 Million CNY | 91.69% |
| 2020 Q1 | 119.34 Million CNY | -43.49% |
| 2020 Q2 | 240.66 Million CNY | 101.65% |
| 2020 FY | 816.89 Million CNY | 30.98% |
| 2020 Q3 | 217.69 Million CNY | -9.54% |
| 2020 Q4 | 239.18 Million CNY | 9.87% |
| 2019 Q3 | 152.88 Million CNY | -2.42% |
| 2019 Q1 | 102.89 Million CNY | -45.12% |
| 2019 Q2 | 156.67 Million CNY | 52.26% |
| 2019 FY | 623.66 Million CNY | 35.17% |
| 2019 Q4 | 211.2 Million CNY | 38.15% |
| 2018 Q1 | 68.61 Million CNY | -56.47% |
| 2018 FY | 461.38 Million CNY | 9.96% |
| 2018 Q4 | 187.49 Million CNY | 92.47% |
| 2018 Q3 | 97.41 Million CNY | -9.7% |
| 2018 Q2 | 107.87 Million CNY | 57.22% |
| 2017 Q2 | 94.65 Million CNY | 34.99% |
| 2017 FY | 419.58 Million CNY | 33.24% |
| 2017 Q4 | 157.62 Million CNY | 62.18% |
| 2017 Q3 | 97.19 Million CNY | 2.68% |
| 2017 Q1 | 70.12 Million CNY | 8.58% |
| 2016 Q1 | 42.3 Million CNY | -45.88% |
| 2016 FY | 314.92 Million CNY | 57.1% |
| 2016 Q4 | 64.57 Million CNY | -51.03% |
| 2016 Q3 | 131.86 Million CNY | 73.13% |
| 2016 Q2 | 76.16 Million CNY | 80.03% |
| 2015 Q3 | 40.74 Million CNY | 0.0% |
| 2015 Q4 | 78.17 Million CNY | 91.88% |
| 2015 FY | 200.45 Million CNY | 65.34% |
| 2014 FY | 121.24 Million CNY | 39.43% |
| 2013 FY | 86.95 Million CNY | 25.72% |
| 2012 FY | 69.16 Million CNY | -10.38% |
| 2011 FY | 77.17 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | -3693.519% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | -186.295% |